Colombia Region of the Americas

I. Epidemiological pro le
Population (UN Population Division) 2017 % Parasites and vectors
High transmission (>1 case per 1000 population) 4.9M 10 Major plasmodium
P.falciparum: 58 (%) , P.vivax: 42 (%)
Low transmission (0-1 case per 1000 population) 5.9M 12 species:
Malaria free (0 cases) 38.2M 78 Major anopheles An. darlingi, An. albimanus, An. nuneztovari, An. neivai, An. punctimacula, An.
Total 49.1M species: pseudopunctipennis

Reported cases and deaths Estimates

Reported con rmed cases (health facility): 52 805 Estimated cases: 80.4K [59.9K, 103.4K]
Con rmed cases at community level: -  
Con rmed cases from private sector: -  
Reported deaths: 19 Estimated deaths: 0

II. Intervention policies and strategies

Yes/ Year
Intervention Policies/Strategies Medicine Year adopted
No adopted Antimalaria treatment policy
ITN ITNs/LLINs distributed free of charge Yes 2012 First-line treatment of uncon rmed malaria - -
ITNs/LLINs distributed to all age groups Yes 2012 First-line treatment of P. falciparum AL+PQ 2006
IRS IRS is recommended Yes 2012 For treatment failure of P. falciparum QN+CL 2004
DDT is used for IRS No 2012 Treatment of severe malaria AS -
Larval control Use of Larval Control Yes 2012 Treatment of P. vivax CQ+PQ(14d) 1960s
IPT IPT used to prevent malaria during pregnancy NA 2012 Dosage of primaquine for radical treatment of P. vivax 0.25 mg/Kg (14 days)
Diagnosis Patients of all ages should receive diagnostic test Yes 2012 Type of RDT used P.f + P.v speci c (Combo)
Malaria diagnosis is free of charge in the public sector Yes 2012
Therapeutic ef cacy tests (clinical and parasitological failure, %)
Treatment ACT is free for all ages in public sector Yes 2012 Medicine Year Min Median Max Follow-up No. of studies Species
The sale of oral artemisinin-based monotherapies (oAMTs) No 2012 AL 2011-2013 0 0 0 28 days 4 P. falciparum
Single dose of primaquine (0.25 mg base/kg) is used as gametocidal CQ 2011-2011 0 0 0 28 days 1 P. vivax
Yes 2012
medicine for P. falciparum CQ+PQ 2012-2013 0 0 0 28 days 2 P. vivax
Primaquine is used for radical treatment of P. vivax Yes 2012
G6PD test is a requirement before treatment with primaquine No - Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (2017)
Directly observed treatment with primaquine is undertaken Yes 2012 Insecticide class Years (%) sites1 Vectors2 Used3
System for monitoring of adverse reaction to antimalarials exists Yes 2012 Carbamates - - - No
Surveillance ACD for case investigation (reactive) Yes 2012 Organochlorines 2011-2017 10.71% (28) An. Darlingi No
ACD at community level of febrile cases (pro-active) Yes 2012 Organophosphates 2011-2017 0% (28) - Yes

Mass screening is undertaken No 2012 Pyrethroids 2011-2017 30.23% (43) An. albimanus, An. darlingi, An. nuneztovari s.l. Yes
1
Uncomplicated P. falciparum cases routinely admitted Yes 2012 Percent of sites for which resistance con rmed and total number of sites that reported data (n)
2
Uncomplicated P. vivax cases routinely admitted Yes 2012 Principal vectors that exhibited resistance
3
Case and foci investigation undertaken 2012 Class used for malaria vector control in 2017
Case reporting from private sector is mandatory Yes 2012
III. Charts Sources of nancing Government expenditure by intervention in 2017
40M

30M

Contribution($USm)

20M

10M

0M
05

06

07

08

09

10

11

12

13

14

15

16

17
20

20

20

20

20

20

20

20

20

20

20

20

20
Insecticides & spray materials ITNs Diagnostic testing
Others WHO/UNICEF USAID/PMI Worldbank (USD) Antimalarial medicines Monitoring and evaluation
Global Fund (USD) Government contribution Human resources & technical assistance Management and other costs

IV. Coverage Coverage of ITN and IRS Cases tested and treated in public sector
100 100%

75 75%

(%)Suspected cases tested

Population

50
50%

25
25%

0
0%
05

06

07

08

09

10

11

12

13

14

15

16

17
20

20

20

20

20

20

20

20

20

20

20

20

20

05

06

07

08

09

10

11

12

13

14

15

16

1 7
20

20

20

20

20

20

20

20

20

20

20

20

20
At high risk protected with ITNs At high risk protected with IRS
% of the population who slept under an ITN the previous night (survey) Suspected cases tested Antimalarials distributed vs reported cases
% of households with at least 1 ITN (survey) Primaquine distributed vs reported P. v. cases

V. Impact Cases treated Test positivity

100% 100%

75% 75%
Tests (%)

50%
(%)

50%

25%
25%

0%
0%
5

08

09

10

11

12

13

15

16

17
0

1
20

20

20

20

20

20

20

20

20

20

20

20

20

05

06

07

09

10

11

12

13

14

15

16

17
0
20

20

20

20

20

20

20

20

20

20

20

20

20

% fever cases <5 seeking treatment at public HF (survey)

Reporting completeness Slide positivity rate RDT positivity rate

Source: DHS 2005, 2010

 
V. Impact Con rmed malaria cases per 1000 and ABER Malaria admissions and deaths
25 10 2000 100

20 8
1500 75

Cases per 1000

Admissions
15 6

Deaths
ABER (%)
1000 50

10 4

500 25

5 2

0 0
0 0

05

06

07

08

09

10

11

12

13

14

15

16

17
20

20

20

20

20

20

20

20

20

20

20

20

20
05

06

07

08

09

10

11

12

13

14

15

16

17
20

20

20

20

20

20

20

20

20

20

20

20

20
Admissions (all species) Admissions (P. vivax)) Deaths (all species)
ABER Cases(all species) Cases (P. vivax) Deaths (P. vivax))

Footnotes
(est.) : WHO estimates based on the survey

World Malaria Report 2018